Pfizer to buy RSV drugmaker for $525M

By Becker's Hospital Review - Healthcare News in Becker's Hospital Review, Channels, Featured
April 8, 2022

Pfizer is set to acquire ReViral, a drugmaker focusing on respiratory syncytial virus therapeutics, for $525 million.

Read the full post on Becker's Hospital Review - Healthcare News

Becker's Hospital Review - Healthcare News